Ondine Biomedical Inc (AIM:OBI) said that a recent study published in the journal Public Health Practice has demonstrated the effectiveness of its nasal photodisinfection program in reducing COVID-19 positivity rates at a major meat packing plant in Western Canada.
The program, implemented alongside standard safety measures recommended by the US Centre for Diseases Control and Prevention (CDC), achieved a remarkable reduction of over 99% in the expected positivity rate.
Quadrise PLC (AIM:QED) told investors that its paused project in Morocco has now received necessary parts and spares, and it looks forward to resuming the fuel trial “at the next available opportunity".
It comes after the trial was disrupted in May due to a mechanical component in the fuel delivery system failing.
Cordiant Digital Infrastructure Ltd (LSE:CORD) has reported full-year 2023 results demonstrating robust growth in net asset value (NAV), with per-share growth of 10% or 10.5p on a total return basis, reaching 113.4p.
The sector-focused specialist owner and operator of digital infrastructure increased its net assets to £875.7mln compared to £822.3mln in 2022.
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has reported an encouraging growth trajectory for its erectile dysfunction gel, Eroxon.
In an update ahead of the company's annual general meeting, the firm announced that initial orders and market demand for the product had met expectations, with net revenues for the six months ending 30 June 2023 expected to reach at least £1.5mln.
Anglo Asian Mining PLC (AIM:AAZ, OTC:AGXKF) confirmed it expects the first of its two new mines under construction, Gilar, to move into production later this year.
Gilar, along with Zafar, its other new mine, is crucial in the company’s plans to become a mid-tier copper producer within five years, said chief executive Reza Vaziri ahead of its AGM.
Biotech firm Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) has reported significant progress in its quest to treat Midkine-expressing cancers.
The programme uses anti-cancer RNA oligonucleotides, small DNA-like molecules used in gene therapy, and has shown over 90% efficacy in laboratory tests on human liver and neuroblastoma cancer cells.
NetScientific PLC (AIM:NSCI), an investment and commercialisation group specialising in life science, sustainability, and industrial technology companies, has successfully concluded a new investment round, raising £3.2mln for its portfolio company Vortex Biotech Holdings Limited.
This funding round was led by EMV Capital.
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said important preclinical work is starting on a programme to produce a breakthrough oral vaccine - a venture that is backed by non-dilutive grant funding from the Irish government's Disruptive Technologies Innovation Fund, investors were told.
The update comes as the Poolbeg-led EncOVac Consortium enters the project's next phase to validate the encapsulation process, which is expected to be completed in the second half of this year.
Powerhouse Energy Group PLC (AIM:PHE) (PHE) said it has completed the acquisition of the remaining shares in green engineering company Engsolve that it did not already own for £0.57mln in cash.
The company has been working with the Bridgend-based firm on its plastics-to-hydrogen projects at the Protos site near Chester as well as more recent prospective projects.
Ora Banda Mining Ltd (ASX:OBM) has successfully completed the sale of four non-core exploration tenements to Beacon Minerals Ltd.
The completion of the Beacon transaction marks a milestone for Ora Banda and the company has received the full consideration of $2.5 million (excluding GST) from Beacon.
European Lithium Ltd (ASX:EUR, OTCQB:EULIF) has strengthened its critical minerals standing in the heart of Europe by completing the acquisition of highly prospective lithium ground in the resource-rich Styria mining district of Austria near its advanced Wolfsberg Lithium Project.
